Subcutaneous remdesivir administration prevents interstitial pneumonia in rhesus macaques inoculated with SARS-CoV-2

Brandi N. Williamson(National Institutes of Health), Emmie de Wit(National Institutes of Health), Patrick W. Hanley(National Institutes of Health), Manmeet Singh(National Institutes of Health), Raju Subramanian(Gilead Sciences (United States)), Diane S. Lye(Gilead Sciences (United States)), Darius Babusis(Gilead Sciences (United States)), Tomáš Cihlář(Gilead Sciences (United States)), Greg Saturday(National Institutes of Health), Catharine M. Bosio(National Institutes of Health), Atsushi Okumura(National Institutes of Health), Benjamin Schwarz(National Institutes of Health), Jamie Lovaglio(National Institutes of Health), Danielle Porter(Gilead Sciences (United States)), Myndi G. Holbrook(National Institutes of Health), Elaine Haddock(National Institutes of Health), Friederike Feldmann(National Institutes of Health), Lizzette Pérez-Pérez(National Institutes of Health), Richard L. Mackman(Gilead Sciences (United States))
Antiviral Research
January 13, 2022
10.1016/j.antiviral.2022.105246
Cited by 4

Related Papers

SARS and MERS: recent insights into emerging coronaviruses
|Nature Reviews Microbiology|2016|3.7k
Airborne Transmission of Influenza A/H5N1 Virus Between Ferrets
|Science|2012|1.7k
Coronavirus Susceptibility to the Antiviral Remdesivir (GS-5734) Is Mediated by the Viral Polymerase and the Proofreading Exoribonuclease
|mBio|2018|1.5k
Animal models for COVID-19
|Nature|2020|877
H5N1 Virus Attachment to Lower Respiratory Tract
|Science|2006|700